



Docket No.: VPI/02-129 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Mark Ledebuer, et al.
SERIAL NUMBER: 10/657,811 EXAMINER: Not Yet Assigned
FILING DATE: September 8, 2003 ART UNIT: 1614
FOR: ISOXAZOLES AND USES THEREOF

March 16, 2004
Cambridge, Massachusetts

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. (37 C.F.R. §1.97).

A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

APPLICANTS: Ledeboer, et al.
U.S.S.N.: 10/657,811

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/02-121 US.

Respectfully submitted,



Karoline K. M. Shair, Reg. No. 44,332
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
 130 Waverly Street
 Cambridge, Massachusetts 02139
 Tel: (617) 444-6536
 Fax: (617) 444-6483



Docket No.: VPI/02-121 US

Certificate Of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On March 16, 2004
Date

1. Information Disclosure Statement (in duplicate);
2. PTO-1449 Form (in duplicate); and
3. Cited References (B1 and C1);
4. This Return Postcard Receipt.

Karen DiRocco
Signature

Karen DiRocco
Typed or printed name of person signing Certificate